Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy

Clinical Endocrinology

Volumn 50, Issue 3, 1999, Pages 373-379

  Gerding, M N ^a   Van Der Zant, F M ^a   Van Royen, E A ^a   Koornneef, L ^a   Krenning, E P ^b   Wiersinga, W M ^a   Prummel, M F ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INDIUM 111; OCTREOTIDE; PENTETIC ACID; PENTETREOTIDE; TECHNETIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EYE DISEASE; FEMALE; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; OBSERVER VARIATION; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; THYROID SCINTISCANNING;

ADULT; EVALUATION STUDIES; FEMALE; GRAVES DISEASE; HORMONES; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; OBSERVER VARIATION; OCTREOTIDE; ORBIT; PAROTID GLAND; PENTETIC ACID; PREDICTIVE VALUE OF TESTS; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0005416301     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1999.00681.x     Document Type: Article

References (15)

1. Burch, H.B. & Wartofsky, L. (1993) Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocrine Reviews, 14, 747-793.
2. Claus, J.J., Dubois, E.A., Booij, J., Habraken, J., De Munck, J.C., Van Herk, M., Verbeeten, B. Jr & Van Royen, E.A. (1997) Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography. European Journal of Nuclear Medicine, 24, 602-608.
3. Gerding, M.N., Prummel, M.F., Kalmann, R., Koornneef, L. & Wiersinga, W.M. (1998) Colour slides are useful in assessing changes in soft-tissue involvement in Graves' ophthalmopathy. journal of Endocrinological Investigations, 21, 459-462.
4. Hiromatsu, Y., Kojima, K. & Ishisaka, N. (1992) Role of magnetic resonance imaging in thyroid-associated-ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid, 2, 299-305.
5. Kahaly, G., Diaz, M., Just, M., Beyer, J. & Lieb, W. (1995) Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy. Thyroid, S, 107-111.
6. Kahaly, G., Gorges, R., Diaz, M., Hommel, G. & Bockisch, A. (1998) indium-111-Pentetreotide in Graves disease. Journal of Nuclear Medicine, 39, 533-536.
7. Krassas, G.E., Dumas, A., Pontikides, N. & Kaltsas, T. (1995) Somatostatin receptor scinti-graphy and octreotide treatment in patients with thyroid eye disease. Clinical Endocrinology, 42, 571-580.
8. Krassas, G.E., Kaltsas, Th., Dumas, A., Pontikides, N. & Tolis, G. (1997) Lanreotide in the treatment of patients with thyroid eye disease. European Journal of Endocrinology, 136, 416-422.
9. 3]-octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine, 20, 716-731.
10. 111In-octreotide. Thyroid, 7, 21-29.
11. Mourits, M.Ph., Prummel, M.F., Wiersinga, W.M. & Koornneef, L. (1994) Measuring eye movements in Graves' ophthalmopathy. Ophthalmology, 101, 1341-1346.
12. Mourits, M.Ph., Prummel, M.F., Wiersinga, W.M. & Koornneef, L. (1997) Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology, 47, 9-14.
13. 111In-DTPA-D-Phe]octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? Journal of Clinical Endocrinology and Metabolism, 79, 1845-1851.
14. Prummel, M.F. & Wiersinga, W.M. (1995) Medical management of Graves' ophthalmopathy. Thyroid, 5, 231-234.
15. Werner, S.C. (1977) Modification of the classification of the eye changes in Graves' disease: Recommendations of the ad hoc committee of the American Thyroid Association. Journal of Clinical Endocrinology and Metabolism, 44, 203-204.